Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that it will deliver two poster presentations at the 20th PEGS Boston Summit, the Essential Protein and Antibody Engineering Summit, being held May 13-17, 2024 in Boston, MA and virtually.
波士顿,2024年5月8日(GLOBE NEWSWIRE)——Cue Biopharma, Inc.(纳斯达克股票代码:CUE)是一家处于临床阶段的生物制药公司,正在开发一种用于选择性调节疾病特异性T细胞的新型治疗生物制剂。该公司今天宣布,它将在2024年5月13日至17日在波士顿举行的第20届PEGS波士顿峰会,即必需蛋白和抗体工程峰会上发表两份海报演讲,MA 和虚拟。
Presentation Details
演示详情
Date and Time: Monday, May 13 from 7:00 a.m. – 4:30 p.m. and Tuesday, May 14 from 9:00 a.m. – 12:00 p.m. EDT
Session: Poster Session A
Poster number: A028
Title: Immuno-STATs for Targeted Depletion of B Cells in Autoimmune Diseases
Presenter: Nitin Kumar, Scientist, Biologics Discovery and Innovation, Cue Biopharma
日期和时间:美国东部时间5月13日星期一上午7点至下午4点30分以及5月14日星期二上午9点至中午12点
会议:海报会议 A
海报编号:A028
标题:用于自身免疫性疾病中 B 细胞靶向消耗的免疫统计数据
主持人:Nitin Kumar,Cue Biopharma 生物制剂发现与创新科学家
Dr. Kumar will discuss Cue Biopharma's newly deployed CUE-500 series of bispecific Immuno-STAT biologics, designed to redirect and activate cytotoxic anti-viral memory T cells to deplete pathogenic B cells, which is a therapeutically relevant mechanism for the treatment of several autoimmune diseases.
库马尔博士将讨论Cue Biopharma新部署的 CUE-500 系列双特异性Immuno-Stat生物制剂,该生物制剂旨在重定向和激活细胞毒性抗病毒记忆T细胞,消耗致病性B细胞,这是一种与治疗相关的机制,用于治疗多种自身免疫性疾病。
Date and Time: Tuesday, May 14 from 2:00 p.m. – 4:00 p.m. and Wednesday, May 15 from 9:00 a.m. – 7:30 p.m. EDT
Session: Poster Session B
Poster number: B023
Title: Immuno-STATs (ISTs): A Novel and Unique T-Cell Engager Platform for the Treatment of Immuno-Oncology and Autoimmune Diseases
Presenter: Ahmet Vakkasoglu, Associate Director, Biologics Discovery and Innovation, Cue Biopharma
日期和时间:美国东部时间5月14日星期二下午2点至下午4点以及5月15日星期三上午9点至晚上7点30分
会议:海报会议 B
海报编号:B023
标题:Immuno-Stats(iST):用于治疗免疫肿瘤学和自身免疫性疾病的新颖而独特的T细胞参与者平台
主持人:艾哈迈德·瓦卡索格鲁,Cue Biopharma生物制剂发现与创新副总监
Dr. Vakkasoglu will present an overview of Cue Biopharma's Immuno-STAT platform and biologics. This will include a discussion of our lead oncology assets, which have demonstrated clinical anti-tumor activity, as well as an overview of our next generation platforms and molecules for the treatment of cancer, autoimmune and inflammatory diseases.
Vakkasoglu博士将概述Cue Biopharma的免疫统计平台和生物制剂。这将包括讨论我们的主要肿瘤学资产,这些资产已显示出临床抗肿瘤活性,以及概述我们用于治疗癌症、自身免疫和炎症性疾病的下一代平台和分子。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
Cue Biopharma
临床阶段的生物制药公司Cue Biopharma正在开发一类新型的可注射生物制剂,用于直接在患者体内选择性地参与和调节疾病特异性T细胞。该公司的专有平台Immuno-Stat (选择性靶向和改变 T 细胞) 生物制剂旨在通过选择性调节疾病特异性T细胞来利用人体内在免疫系统的治疗潜力,而不会受到广泛的全身免疫调节的不利影响。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
我们总部位于马萨诸塞州波士顿,由经验丰富的管理团队和独立董事会领导,他们在免疫学和免疫肿瘤学以及蛋白生物制剂的设计和临床开发方面拥有深厚的专业知识。
For more information please visit and follow us on X and LinkedIn.
欲了解更多信息,请访问并在 X 和 LinkedIn 上关注我们。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投资者联系人
玛丽·坎皮内尔
企业传播高级董事
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒体联系人
乔纳森·帕帕斯
LifeSci
jpappas@lifescicomms.com